在第三级记忆诊所环境中,对抗粉样蛋白治疗的"现实世界"资格
Sinthujah Vigneswaran1,2,3, Everard G B Vijverberg2, Frederik Barkhof4
1Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
概括
在阿尔茨海默病 (AD) 中,抗粉样蛋白治疗 (AAT) 的资格在现实世界的记忆诊所中是有限的. 只有6%的新患者符合严格的标准,这凸显了AAT可访问性面临的挑战.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 对阿尔茨海默病 (AD) 的抗粉样蛋白治疗 (AAT) 的社会影响取决于患者的资格.
- 目前的估计表明1-18%的AD患者可能有资格,但现实数据很少.
- 这项研究评估了AAT在第三级记忆诊所环境中的资格.
研究的目的:
- 评估患者在第三级记忆诊所接受抗粉样蛋白治疗 (AAT) 的现实资格.
- 根据经批准的指导方针,确定满足AAT标准的患者比例.
主要方法:
- 阿姆斯特丹阿尔茨海默症中心 (2020-2022) 的1309名新患者接受了标准化诊断工作.
- 使用lecanemab的批准标签指南确定了AAT的资格.
- 排除标准包括粉样蛋白状况,微血细胞计数,阿波利波蛋白E ε4/ε4同性以及抗凝剂的使用.
主要成果:
- 在1309名患者中,514名 (39%) 患有临床轻度认知障碍 (MCI) 或AD.
- 最初,有108名患者 (占所有患者的8%,MCI/AD患者的21%) 符合核心标准.
- 在排除后,79名患者 (全部的6%,MCI/AD的15%) 符合AAT的资格.
结论:
- 在第三级记忆诊所中,AAT的现实资格是有限的.
- 根据目前的指导方针,符合AAT条件的患者比例很低.
- 这些发现强调了阿尔茨海默病AAT广泛临床应用的挑战.
相关概念视频
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:30Dementia
108
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
108
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
111
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
111